Icosavax reports durability data for VLP vaccine IVX-121 against RSV

Icosavax provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody nAb response against RSV, lasting for at least six months after a single administration of IVX-121. "We are delighted to share the six-month immunogenicity data from our Phase 1/1b trial of IVX-121. The potential for long-lasting immune responses was part of our founding hypothesis and preclinical rationale for developing combination VLP vaccines, so it is exciting to see this supportive initial clinical data on durability from our platform," said Adam Simpson, Chief Executive Officer of Icosavax. "We continue to believe that there is a need for better vaccines, in particular the potential for combination respiratory vaccines with longer-lasting protection and low reactogenicity."